Literature DB >> 31150623

CerS6-Derived Sphingolipids Interact with Mff and Promote Mitochondrial Fragmentation in Obesity.

Philipp Hammerschmidt1, Daniela Ostkotte2, Hendrik Nolte3, Mathias J Gerl4, Alexander Jais1, Hanna L Brunner2, Hans-Georg Sprenger3, Motoharu Awazawa1, Hayley T Nicholls1, Sarah M Turpin-Nolan1, Thomas Langer3, Marcus Krüger5, Britta Brügger2, Jens C Brüning6.   

Abstract

Ectopic lipid deposition and altered mitochondrial dynamics contribute to the development of obesity and insulin resistance. However, the mechanistic link between these processes remained unclear. Here we demonstrate that the C16:0 sphingolipid synthesizing ceramide synthases, CerS5 and CerS6, affect distinct sphingolipid pools and that abrogation of CerS6 but not of CerS5 protects from obesity and insulin resistance. We identify proteins that specifically interact with C16:0 sphingolipids derived from CerS5 or CerS6. Here, only CerS6-derived C16:0 sphingolipids bind the mitochondrial fission factor (Mff). CerS6 and Mff deficiency protect from fatty acid-induced mitochondrial fragmentation in vitro, and the two proteins genetically interact in vivo in obesity-induced mitochondrial fragmentation and development of insulin resistance. Our experiments reveal an unprecedented specificity of sphingolipid signaling depending on specific synthesizing enzymes, provide a mechanistic link between hepatic lipid deposition and mitochondrial fragmentation in obesity, and define the CerS6-derived sphingolipid/Mff interaction as a therapeutic target for metabolic diseases.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Year:  2019        PMID: 31150623     DOI: 10.1016/j.cell.2019.05.008

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  75 in total

Review 1.  Function and regulation of the divisome for mitochondrial fission.

Authors:  Felix Kraus; Krishnendu Roy; Thomas J Pucadyil; Michael T Ryan
Journal:  Nature       Date:  2021-02-03       Impact factor: 49.962

Review 2.  Is Mitochondrial Dysfunction a Common Root of Noncommunicable Chronic Diseases?

Authors:  Alexis Diaz-Vegas; Pablo Sanchez-Aguilera; James R Krycer; Pablo E Morales; Matías Monsalves-Alvarez; Mariana Cifuentes; Beverly A Rothermel; Sergio Lavandero
Journal:  Endocr Rev       Date:  2020-06-01       Impact factor: 19.871

Review 3.  Reign in the membrane: How common lipids govern mitochondrial function.

Authors:  Katsuhiko Funai; Scott A Summers; Jared Rutter
Journal:  Curr Opin Cell Biol       Date:  2020-02-24       Impact factor: 8.382

4.  Machine learning reveals serum sphingolipids as cholesterol-independent biomarkers of coronary artery disease.

Authors:  Annelise M Poss; J Alan Maschek; James E Cox; Benedikt J Hauner; Paul N Hopkins; Steven C Hunt; William L Holland; Scott A Summers; Mary C Playdon
Journal:  J Clin Invest       Date:  2020-03-02       Impact factor: 14.808

Review 5.  The integrative biology of type 2 diabetes.

Authors:  Michael Roden; Gerald I Shulman
Journal:  Nature       Date:  2019-12-04       Impact factor: 49.962

Review 6.  The role of ceramides in metabolic disorders: when size and localization matters.

Authors:  Sarah M Turpin-Nolan; Jens C Brüning
Journal:  Nat Rev Endocrinol       Date:  2020-02-14       Impact factor: 43.330

Review 7.  The cell biology of mitochondrial membrane dynamics.

Authors:  Marta Giacomello; Aswin Pyakurel; Christina Glytsou; Luca Scorrano
Journal:  Nat Rev Mol Cell Biol       Date:  2020-02-18       Impact factor: 94.444

Review 8.  Ceramides in Metabolism: Key Lipotoxic Players.

Authors:  Bhagirath Chaurasia; Scott A Summers
Journal:  Annu Rev Physiol       Date:  2020-11-06       Impact factor: 19.318

Review 9.  Metabolic Messengers: ceramides.

Authors:  Scott A Summers; Bhagirath Chaurasia; William L Holland
Journal:  Nat Metab       Date:  2019-10-24

Review 10.  Dietary carbohydrates and fats in nonalcoholic fatty liver disease.

Authors:  Hannele Yki-Järvinen; Panu K Luukkonen; Leanne Hodson; J Bernadette Moore
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2021-07-13       Impact factor: 46.802

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.